Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Orbis Pharmaceuticals

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000979 15 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx15product presentations
G4generic molecules
DF3dosage-form groups
TA2therapeutic areas
PKR15current price records
REG13registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage93%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixOrbis PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/orbis-pharmaceuticalsGenerated 10 Aug 2026CNS & mental health12 · 80%Anti-infectives3 · 20%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioOrbis PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/orbis-pharmaceuticalsGenerated 10 Aug 202615presentationsTablet13 · 87%Capsule1 · 7%Cream1 · 7%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionOrbis PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/orbis-pharmaceuticalsGenerated 10 Aug 202614comparable productsBelow market median6 · 43%Near market median4 · 29%Above market median4 · 29%Company median price position-3.4%Lowest-price equivalents2Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsOrbis PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/orbis-pharmaceuticalsGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,4 shared100% overlapM/s. Genix Pharma (Pvt) Ltd.4 shared100% overlapPharmasol (Pvt) Ltd.4 shared100% overlapMediate Pharmaceutical Pvt Ltd4 shared100% overlapBio-Labs(Pvt) Ltd4 shared100% overlapAGP Limited4 shared100% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

CNS & mental health12 products · 80%
Anti-infectives3 products · 20%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antipsychotics12 products · 80%
Macrolide antibacterials2 products · 13%
Antifungals1 products · 7%
Formulation footprint

Dosage forms

Tablet13 products
Capsule1 products
Cream1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 OridoneRisperidone 5presentations 0.5 mg, 1 mg, 2 mg, 3 mg · Tablet #2 QutoQuetiapine 4presentations 100 mg, 25 mg · Tablet #3 Quto XRQuetiapine 3presentations 150 mg, 300 mg, 50 mg · Tablet #4 AzisoftAzithromycin 2presentations 250 mg, 500 mg · Capsule, Tablet #5 Trybis w/wTerbinafine 1presentations 1 % · Cream
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median643% of comparable products
Near market median4within ±5% of median
Above market median429% of comparable products
Lowest-price equivalents2ties included
Company median price position -3.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Trybis w/w 1 %Terbinafine · Cream · 10g PKR 22.30/g-20.5% vs market median Quto XR 150 mgQuetiapine · Tablet · 1 x 10's PKR 77.11/tablet-18.0% vs market median Quto 100 mgQuetiapine · Tablet · 1 x 10's PKR 59.47/tablet-16.1% vs market median Quto 25 mgQuetiapine · Tablet · 1 x 10's PKR 19.82/tablet-5.1% vs market median Quto 25 mgQuetiapine · Tablet · 3 x 10's PKR 19.82/tablet-5.1% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 4shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 4shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 4shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 4shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 4shared generics AGP Limited220 products · 68 generics 4shared generics
Regulatory & price activity

Observed database signals

Registration numbers13
Price-history records17
Products with price history1
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

15 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Azisoft Azithromycin 250 mg Capsule 6's 127036 PKR 292.93 PKR 48.82/capsule Near median
Azisoft Azithromycin 500 mg Tablet 6's 127831 PKR 545.15 PKR 90.86/tablet 7% above median
Oridone Risperidone 4 mg Tablet 1 x 10's 127829 PKR 773.12 PKR 77.31/tablet 7% above median
Oridone Risperidone 0.5 mg Tablet 2 x 10's 127830 PKR 285.46 PKR 14.27/tablet Near median
Oridone Risperidone 2 mg Tablet 1 x 10's 127826 PKR 386.56 PKR 38.66/tablet 7% above median
Oridone Risperidone 1 mg Tablet 1 x 10's 127827 PKR 237.88 PKR 23.79/tablet 5% above median
Oridone Risperidone 3 mg Tablet 1 x 10's 127828 PKR 594.70 PKR 59.47/tablet Near median
Quto Quetiapine 25 mg Tablet 1 x 10's 127823 PKR 198.23 PKR 19.82/tablet 5% below median
Quto Quetiapine 25 mg Tablet 2 x 10's 127823 PKR 396.47 PKR 19.82/tablet 5% below median
Quto Quetiapine 100 mg Tablet 1 x 10's 127822 PKR 594.70 PKR 59.47/tablet 16% below median
Quto Quetiapine 25 mg Tablet 3 x 10's 127823 PKR 594.70 PKR 19.82/tablet 5% below median
Quto XR Quetiapine 150 mg Tablet 1 x 10's 127821 PKR 771.13 PKR 77.11/tablet 18% below median
Quto XR Quetiapine 300 mg Tablet 1 x 10's 127824 PKR 1,284.56 PKR 128.46/tablet Near median
Quto XR Quetiapine 50 mg Tablet 10 x 10's 127825 PKR 3,938.92 PKR 39.39/tablet No comparator
Trybis w/w Terbinafine 1 % Cream 10g 135234 PKR 223.00 PKR 22.30/g 21% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.